Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
Stopped early · Phase 2
Conditions studied: Leukemia
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have chronic myelogenous leukemia in chronic or accelerated phase.
Key facts
- Study ID
- NCT00023881
- Run by
- M.D. Anderson Cancer Center
- People needed
- 7
- Starts
- 2001-07-02
- Expected to finish
- 2005-03-01
- Last updated by the study team
- 2018-11-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- MD Anderson Cancer Center at University of Texas — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.